The global market for Gastric Cancer Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gastric Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gastric Cancer Diagnostics by region & country, by Type, and by Application.

The Gastric Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastric Cancer Diagnostics.

Market Segmentation

Scope of Gastric Cancer Diagnostics - Market Report

Report Metric	Details
Report Name	Gastric Cancer Diagnostics - Market
CAGR	5%
Segment by Type:	Instrument Reagent Consumables Service
Segment by Application	Male Female
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Myriad Genetics, ACON Laboratories, Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific, F. Hoffmann-La Roche, General Electric, Agilent Technologies, Endofotonics, Biohit Oyj, BIOCEPT, FOUNDATION MEDICINE, DiaSorin S.p.A, Paragon Genomics, BIOMÉRIEUX, QIAGEN
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gastric Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gastric Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gastric Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Gastric Cancer Diagnostics - Market report?

Ans: The main players in the Gastric Cancer Diagnostics - Market are Myriad Genetics, ACON Laboratories, Teco Diagnostics, Vela Diagnostics, Abbott, AdvaCare Pharma, Fujirebio (An H.U. Group company), Thermo Fisher Scientific, F. Hoffmann-La Roche, General Electric, Agilent Technologies, Endofotonics, Biohit Oyj, BIOCEPT, FOUNDATION MEDICINE, DiaSorin S.p.A, Paragon Genomics, BIOMÉRIEUX, QIAGEN

What are the Application segmentation covered in the Gastric Cancer Diagnostics - Market report?

Ans: The Applications covered in the Gastric Cancer Diagnostics - Market report are Male, Female

What are the Type segmentation covered in the Gastric Cancer Diagnostics - Market report?

Ans: The Types covered in the Gastric Cancer Diagnostics - Market report are Instrument, Reagent Consumables, Service

1 Market Overview

1.1 Gastric Cancer Diagnostics Product Introduction

1.2 Global Gastric Cancer Diagnostics Market Size Forecast

1.3 Gastric Cancer Diagnostics Market Trends & Drivers

1.3.1 Gastric Cancer Diagnostics Industry Trends

1.3.2 Gastric Cancer Diagnostics Market Drivers & Opportunity

1.3.3 Gastric Cancer Diagnostics Market Challenges

1.3.4 Gastric Cancer Diagnostics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Gastric Cancer Diagnostics Players Revenue Ranking (2023)

2.2 Global Gastric Cancer Diagnostics Revenue by Company (2019-2024)

2.3 Key Companies Gastric Cancer Diagnostics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Gastric Cancer Diagnostics Product Offered

2.5 Key Companies Time to Begin Mass Production of Gastric Cancer Diagnostics

2.6 Gastric Cancer Diagnostics Market Competitive Analysis

2.6.1 Gastric Cancer Diagnostics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Gastric Cancer Diagnostics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Cancer Diagnostics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Instrument

3.1.2 Reagent Consumables

3.1.3 Service

3.2 Global Gastric Cancer Diagnostics Sales Value by Type

3.2.1 Global Gastric Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Gastric Cancer Diagnostics Sales Value, by Type (2019-2030)

3.2.3 Global Gastric Cancer Diagnostics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Male

4.1.2 Female

4.2 Global Gastric Cancer Diagnostics Sales Value by Application

4.2.1 Global Gastric Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Gastric Cancer Diagnostics Sales Value, by Application (2019-2030)

4.2.3 Global Gastric Cancer Diagnostics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Gastric Cancer Diagnostics Sales Value by Region

5.1.1 Global Gastric Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Gastric Cancer Diagnostics Sales Value by Region (2019-2024)

5.1.3 Global Gastric Cancer Diagnostics Sales Value by Region (2025-2030)

5.1.4 Global Gastric Cancer Diagnostics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Gastric Cancer Diagnostics Sales Value, 2019-2030

5.2.2 North America Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Gastric Cancer Diagnostics Sales Value, 2019-2030

5.3.2 Europe Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Gastric Cancer Diagnostics Sales Value, 2019-2030

5.4.2 Asia Pacific Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Gastric Cancer Diagnostics Sales Value, 2019-2030

5.5.2 South America Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Gastric Cancer Diagnostics Sales Value, 2019-2030

5.6.2 Middle East & Africa Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Gastric Cancer Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Gastric Cancer Diagnostics Sales Value

6.3 United States

6.3.1 United States Gastric Cancer Diagnostics Sales Value, 2019-2030

6.3.2 United States Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Gastric Cancer Diagnostics Sales Value, 2019-2030

6.4.2 Europe Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Gastric Cancer Diagnostics Sales Value, 2019-2030

6.5.2 China Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Gastric Cancer Diagnostics Sales Value, 2019-2030

6.6.2 Japan Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Gastric Cancer Diagnostics Sales Value, 2019-2030

6.7.2 South Korea Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Gastric Cancer Diagnostics Sales Value, 2019-2030

6.8.2 Southeast Asia Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Gastric Cancer Diagnostics Sales Value, 2019-2030

6.9.2 India Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Gastric Cancer Diagnostics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Myriad Genetics

7.1.1 Myriad Genetics Profile

7.1.2 Myriad Genetics Main Business

7.1.3 Myriad Genetics Gastric Cancer Diagnostics Products, Services and Solutions

7.1.4 Myriad Genetics Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.1.5 Myriad Genetics Recent Developments

7.2 ACON Laboratories

7.2.1 ACON Laboratories Profile

7.2.2 ACON Laboratories Main Business

7.2.3 ACON Laboratories Gastric Cancer Diagnostics Products, Services and Solutions

7.2.4 ACON Laboratories Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.2.5 ACON Laboratories Recent Developments

7.3 Teco Diagnostics

7.3.1 Teco Diagnostics Profile

7.3.2 Teco Diagnostics Main Business

7.3.3 Teco Diagnostics Gastric Cancer Diagnostics Products, Services and Solutions

7.3.4 Teco Diagnostics Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.3.5 Vela Diagnostics Recent Developments

7.4 Vela Diagnostics

7.4.1 Vela Diagnostics Profile

7.4.2 Vela Diagnostics Main Business

7.4.3 Vela Diagnostics Gastric Cancer Diagnostics Products, Services and Solutions

7.4.4 Vela Diagnostics Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.4.5 Vela Diagnostics Recent Developments

7.5 Abbott, AdvaCare Pharma

7.5.1 Abbott, AdvaCare Pharma Profile

7.5.2 Abbott, AdvaCare Pharma Main Business

7.5.3 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Products, Services and Solutions

7.5.4 Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.5.5 Abbott, AdvaCare Pharma Recent Developments

7.6 Fujirebio (An H.U. Group company)

7.6.1 Fujirebio (An H.U. Group company) Profile

7.6.2 Fujirebio (An H.U. Group company) Main Business

7.6.3 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Products, Services and Solutions

7.6.4 Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.6.5 Fujirebio (An H.U. Group company) Recent Developments

7.7 Thermo Fisher Scientific

7.7.1 Thermo Fisher Scientific Profile

7.7.2 Thermo Fisher Scientific Main Business

7.7.3 Thermo Fisher Scientific Gastric Cancer Diagnostics Products, Services and Solutions

7.7.4 Thermo Fisher Scientific Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.7.5 Thermo Fisher Scientific Recent Developments

7.8 F. Hoffmann-La Roche

7.8.1 F. Hoffmann-La Roche Profile

7.8.2 F. Hoffmann-La Roche Main Business

7.8.3 F. Hoffmann-La Roche Gastric Cancer Diagnostics Products, Services and Solutions

7.8.4 F. Hoffmann-La Roche Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.8.5 F. Hoffmann-La Roche Recent Developments

7.9 General Electric

7.9.1 General Electric Profile

7.9.2 General Electric Main Business

7.9.3 General Electric Gastric Cancer Diagnostics Products, Services and Solutions

7.9.4 General Electric Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.9.5 General Electric Recent Developments

7.10 Agilent Technologies

7.10.1 Agilent Technologies Profile

7.10.2 Agilent Technologies Main Business

7.10.3 Agilent Technologies Gastric Cancer Diagnostics Products, Services and Solutions

7.10.4 Agilent Technologies Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.10.5 Agilent Technologies Recent Developments

7.11 Endofotonics

7.11.1 Endofotonics Profile

7.11.2 Endofotonics Main Business

7.11.3 Endofotonics Gastric Cancer Diagnostics Products, Services and Solutions

7.11.4 Endofotonics Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.11.5 Endofotonics Recent Developments

7.12 Biohit Oyj

7.12.1 Biohit Oyj Profile

7.12.2 Biohit Oyj Main Business

7.12.3 Biohit Oyj Gastric Cancer Diagnostics Products, Services and Solutions

7.12.4 Biohit Oyj Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.12.5 Biohit Oyj Recent Developments

7.13 BIOCEPT

7.13.1 BIOCEPT Profile

7.13.2 BIOCEPT Main Business

7.13.3 BIOCEPT Gastric Cancer Diagnostics Products, Services and Solutions

7.13.4 BIOCEPT Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.13.5 BIOCEPT Recent Developments

7.14 FOUNDATION MEDICINE

7.14.1 FOUNDATION MEDICINE Profile

7.14.2 FOUNDATION MEDICINE Main Business

7.14.3 FOUNDATION MEDICINE Gastric Cancer Diagnostics Products, Services and Solutions

7.14.4 FOUNDATION MEDICINE Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.14.5 FOUNDATION MEDICINE Recent Developments

7.15 DiaSorin S.p.A

7.15.1 DiaSorin S.p.A Profile

7.15.2 DiaSorin S.p.A Main Business

7.15.3 DiaSorin S.p.A Gastric Cancer Diagnostics Products, Services and Solutions

7.15.4 DiaSorin S.p.A Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.15.5 DiaSorin S.p.A Recent Developments

7.16 Paragon Genomics

7.16.1 Paragon Genomics Profile

7.16.2 Paragon Genomics Main Business

7.16.3 Paragon Genomics Gastric Cancer Diagnostics Products, Services and Solutions

7.16.4 Paragon Genomics Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.16.5 Paragon Genomics Recent Developments

7.17 BIOMÉRIEUX

7.17.1 BIOMÉRIEUX Profile

7.17.2 BIOMÉRIEUX Main Business

7.17.3 BIOMÉRIEUX Gastric Cancer Diagnostics Products, Services and Solutions

7.17.4 BIOMÉRIEUX Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.17.5 BIOMÉRIEUX Recent Developments

7.18 QIAGEN

7.18.1 QIAGEN Profile

7.18.2 QIAGEN Main Business

7.18.3 QIAGEN Gastric Cancer Diagnostics Products, Services and Solutions

7.18.4 QIAGEN Gastric Cancer Diagnostics Revenue (US$ Million) & (2019-2024)

7.18.5 QIAGEN Recent Developments

8 Industry Chain Analysis

8.1 Gastric Cancer Diagnostics Industrial Chain

8.2 Gastric Cancer Diagnostics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Gastric Cancer Diagnostics Sales Model

8.5.2 Sales Channel

8.5.3 Gastric Cancer Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Teco Diagnostics

Vela Diagnostics

Thermo Fisher Scientific

Abbott, AdvaCare Pharma

Fujirebio (An H.U. Group company)

Endofotonics

ACON Laboratories

Myriad Genetics

List of Tables

Table 1. Gastric Cancer Diagnostics Market Trends

Table 2. Gastric Cancer Diagnostics Market Drivers & Opportunity

Table 3. Gastric Cancer Diagnostics Market Challenges

Table 4. Gastric Cancer Diagnostics Market Restraints

Table 5. Global Gastric Cancer Diagnostics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Gastric Cancer Diagnostics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Gastric Cancer Diagnostics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Gastric Cancer Diagnostics Product Type

Table 9. Key Companies Time to Begin Mass Production of Gastric Cancer Diagnostics

Table 10. Global Gastric Cancer Diagnostics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Cancer Diagnostics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Gastric Cancer Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Gastric Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Gastric Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Gastric Cancer Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Gastric Cancer Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Gastric Cancer Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Gastric Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Gastric Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Gastric Cancer Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Gastric Cancer Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Gastric Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Gastric Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Gastric Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Gastric Cancer Diagnostics Sales Value by Region (2019-2024) & (%)

Table 27. Global Gastric Cancer Diagnostics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Gastric Cancer Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Gastric Cancer Diagnostics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Gastric Cancer Diagnostics Sales Value, (2025-2030) & (US$ Million)

Table 31. Myriad Genetics Basic Information List

Table 32. Myriad Genetics Description and Business Overview

Table 33. Myriad Genetics Gastric Cancer Diagnostics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Myriad Genetics (2019-2024)

Table 35. Myriad Genetics Recent Developments

Table 36. ACON Laboratories Basic Information List

Table 37. ACON Laboratories Description and Business Overview

Table 38. ACON Laboratories Gastric Cancer Diagnostics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of ACON Laboratories (2019-2024)

Table 40. ACON Laboratories Recent Developments

Table 41. Teco Diagnostics Basic Information List

Table 42. Teco Diagnostics Description and Business Overview

Table 43. Teco Diagnostics Gastric Cancer Diagnostics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Teco Diagnostics (2019-2024)

Table 45. Teco Diagnostics Recent Developments

Table 46. Vela Diagnostics Basic Information List

Table 47. Vela Diagnostics Description and Business Overview

Table 48. Vela Diagnostics Gastric Cancer Diagnostics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Vela Diagnostics (2019-2024)

Table 50. Vela Diagnostics Recent Developments

Table 51. Abbott, AdvaCare Pharma Basic Information List

Table 52. Abbott, AdvaCare Pharma Description and Business Overview

Table 53. Abbott, AdvaCare Pharma Gastric Cancer Diagnostics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Abbott, AdvaCare Pharma (2019-2024)

Table 55. Abbott, AdvaCare Pharma Recent Developments

Table 56. Fujirebio (An H.U. Group company) Basic Information List

Table 57. Fujirebio (An H.U. Group company) Description and Business Overview

Table 58. Fujirebio (An H.U. Group company) Gastric Cancer Diagnostics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Fujirebio (An H.U. Group company) (2019-2024)

Table 60. Fujirebio (An H.U. Group company) Recent Developments

Table 61. Thermo Fisher Scientific Basic Information List

Table 62. Thermo Fisher Scientific Description and Business Overview

Table 63. Thermo Fisher Scientific Gastric Cancer Diagnostics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Thermo Fisher Scientific (2019-2024)

Table 65. Thermo Fisher Scientific Recent Developments

Table 66. F. Hoffmann-La Roche Basic Information List

Table 67. F. Hoffmann-La Roche Description and Business Overview

Table 68. F. Hoffmann-La Roche Gastric Cancer Diagnostics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of F. Hoffmann-La Roche (2019-2024)

Table 70. F. Hoffmann-La Roche Recent Developments

Table 71. General Electric Basic Information List

Table 72. General Electric Description and Business Overview

Table 73. General Electric Gastric Cancer Diagnostics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of General Electric (2019-2024)

Table 75. General Electric Recent Developments

Table 76. Agilent Technologies Basic Information List

Table 77. Agilent Technologies Description and Business Overview

Table 78. Agilent Technologies Gastric Cancer Diagnostics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Agilent Technologies (2019-2024)

Table 80. Agilent Technologies Recent Developments

Table 81. Endofotonics Basic Information List

Table 82. Endofotonics Description and Business Overview

Table 83. Endofotonics Gastric Cancer Diagnostics Products, Services and Solutions

Table 84. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Endofotonics (2019-2024)

Table 85. Endofotonics Recent Developments

Table 86. Biohit Oyj Basic Information List

Table 87. Biohit Oyj Description and Business Overview

Table 88. Biohit Oyj Gastric Cancer Diagnostics Products, Services and Solutions

Table 89. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Biohit Oyj (2019-2024)

Table 90. Biohit Oyj Recent Developments

Table 91. BIOCEPT Basic Information List

Table 92. BIOCEPT Description and Business Overview

Table 93. BIOCEPT Gastric Cancer Diagnostics Products, Services and Solutions

Table 94. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of BIOCEPT (2019-2024)

Table 95. BIOCEPT Recent Developments

Table 96. FOUNDATION MEDICINE Basic Information List

Table 97. FOUNDATION MEDICINE Description and Business Overview

Table 98. FOUNDATION MEDICINE Gastric Cancer Diagnostics Products, Services and Solutions

Table 99. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of FOUNDATION MEDICINE (2019-2024)

Table 100. FOUNDATION MEDICINE Recent Developments

Table 101. DiaSorin S.p.A Basic Information List

Table 102. DiaSorin S.p.A Description and Business Overview

Table 103. DiaSorin S.p.A Gastric Cancer Diagnostics Products, Services and Solutions

Table 104. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of DiaSorin S.p.A (2019-2024)

Table 105. DiaSorin S.p.A Recent Developments

Table 106. Paragon Genomics Basic Information List

Table 107. Paragon Genomics Description and Business Overview

Table 108. Paragon Genomics Gastric Cancer Diagnostics Products, Services and Solutions

Table 109. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of Paragon Genomics (2019-2024)

Table 110. Paragon Genomics Recent Developments

Table 111. BIOMÉRIEUX Basic Information List

Table 112. BIOMÉRIEUX Description and Business Overview

Table 113. BIOMÉRIEUX Gastric Cancer Diagnostics Products, Services and Solutions

Table 114. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of BIOMÉRIEUX (2019-2024)

Table 115. BIOMÉRIEUX Recent Developments

Table 116. QIAGEN Basic Information List

Table 117. QIAGEN Description and Business Overview

Table 118. QIAGEN Gastric Cancer Diagnostics Products, Services and Solutions

Table 119. Revenue (US$ Million) in Gastric Cancer Diagnostics Business of QIAGEN (2019-2024)

Table 120. QIAGEN Recent Developments

Table 121. Key Raw Materials Lists

Table 122. Raw Materials Key Suppliers Lists

Table 123. Gastric Cancer Diagnostics Downstream Customers

Table 124. Gastric Cancer Diagnostics Distributors List

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Gastric Cancer Diagnostics Product Picture

Figure 2. Global Gastric Cancer Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 4. Gastric Cancer Diagnostics Report Years Considered

Figure 5. Global Gastric Cancer Diagnostics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Gastric Cancer Diagnostics Revenue in 2023

Figure 7. Gastric Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Instrument Picture

Figure 9. Reagent Consumables Picture

Figure 10. Service Picture

Figure 11. Global Gastric Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Gastric Cancer Diagnostics Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Male

Figure 14. Product Picture of Female

Figure 15. Global Gastric Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Gastric Cancer Diagnostics Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Gastric Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Gastric Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Gastric Cancer Diagnostics Sales Value (%), (2019-2030)

Figure 28. United States Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 34. China Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 36. China Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 46. India Gastric Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Gastric Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 48. India Gastric Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 49. Gastric Cancer Diagnostics Industrial Chain

Figure 50. Gastric Cancer Diagnostics Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions